

Times political editor Steve Neal, entitled *Harry & Ike The Partnership That Remade the Postwar World*. Mr. Neal is a trained historian and an experienced political journalist. Mr. Neal's fascinating insight and careful attention to detail bring these two extraordinary figures in American history, Presidents Harry S. Truman and Dwight D. Eisenhower, to life. I found this book to be a highly readable history of the relationship of two great Americans.

Dr. Henry Kissinger said, "Harry & Ike sheds important new light on a relationship founded on friendship and a similar heritage, bitterly shattered by politics and reknit by mutual respect at the end of their lives. Drawing on their letters, diaries and memoirs and on personal recollections of associates, Neal gives us fascinating insights into these two 'giants that saved the West.'"

Former Senator Bob Dole stated that, "Harry & Ike is a fair, balanced, and compelling study of two great American presidents. Steve Neal brings both men vividly to life and does justice to his subjects."

This is a book that you will find interesting, informative and enjoyable. Read it, Harry & Ike, by Steve Neal. You won't be sorry; you'd be educated.

REGARDING NOBEL LAUREATE DR.
LEE HARTWELL

HON. DOC HASTINGS

OF WASHINGTON

IN THE HOUSE OF REPRESENTATIVES

Friday, November 16, 2001

Mr. HASTINGS of Washington. Mr. Speaker, I rise today to recognize and honor Dr. Lee Hartwell, the 2001 Nobel Prize winner in the field of medicine.

Each year the Nobel Prize for Medicine is awarded to those who have made important discoveries within the domain of physiology or medicine with the greatest benefit on mankind. I would like to take this opportunity to congratulate the 2001 award winner Dr. Lee Hartwell, President and Director of the Fred Hutchinson Cancer Research Center located in Washington state. I'm proud that innovative research, like that done by Dr. Hartwell, is being conducted in my home state.

Dr. Lee Hartwell, a pioneering geneticist, was awarded the Nobel Prize for Medicine for his discoveries concerning control of the cell cycle. For three decades Dr. Hartwell has conducted research on cell division and has identified molecules that regulate cell division. It's this kind of knowledge that is key to understanding how cancer cells mutate and developing approaches to reverse or prevent that mutation.

With an estimated 24,800 new cancer cases in Washington state alone this year, it's clear that many people will benefit from the hard-work and commitment of Dr. Hartwell.

Thank you for this opportunity to recognize Dr. Hartwell. His discoveries have tremendous implications for life saving cancer therapies and will have an impact on cancer patients and their families for generations to come.

IN HONOR OF BEN TRAINA UPON
HIS RETIREMENT FROM 8 YEARS
ON LOMITA CITY COUNCIL

HON. JANE HARMAN

OF CALIFORNIA

IN THE HOUSE OF REPRESENTATIVES

Friday, November 16, 2001

Ms. HARMAN. Mr. Speaker, I rise today in honor of my constituent and good friend, Ben Traina, who retires this month from the Lomita City Council after years of exceptional service to his community, including two terms as Mayor.

I have known Ben since I first ran for Congress in 1992. Ben was often my host in the City of Lomita, a small town in the true sense of the phrase, nestled in the hustle and bustle of the South Bay of Los Angeles. Ben barely knew me then, but he enthusiastically escorted me to small coffees and community events so that I could meet the residents of his city. We had a great time.

Since then, we have worked closely together on an issue that is a high priority for me. The Lomita Little League is the cornerstone of the Lomita community. Virtually every kid in Lomita plays in the Little League, and the parents are great fans. Baseball is simply what the town does on Saturdays.

For years, the League played on otherwise unusable Navy property, but had to renegotiate the agreement annually. The uncertainty was hard on the community. It was reluctant to make investments in vital capital improvements—such as a new clubhouse and functioning restrooms—or making the infield free of bad hops.

Ben and I worked hard together to develop a system that would serve the League's interest better yet comply with Navy regulations on land use. After months of meetings with Navy personnel, Ben and I negotiated a ten-year license agreement, beginning in 1995, under which the League would be able to use the land for its primary mission—playing baseball.

But a problem remained: the League also needed a way to raise money. For years it had been selling Christmas trees on the lot as its primary source of revenue. But the Navy objected to the procedures for selling the trees and for the past several years, those sales were stopped.

Once again, Ben and I launched a months-long process to re-negotiate the terms of the license agreement and convince the Navy that the League should be able to do its fund-raising. With the help of Assistant Secretary of the Navy, H.T. Johnson, I am happy to report that the Traina-Harman partnership has prevailed, and the Christmas tree sale was approved just in time for this year's Christmas season.

Mr. Speaker, I will miss working with Ben in his capacity as an elected official. But I know we will continue to work together to preserve the ability of Lomita kids and families to enjoy the spirit of baseball.

I am proud of Ben's efforts, and I join the citizens of Lomita in thanking him for exceptional service and wishing him well.

BEST PHARMACEUTICALS FOR
CHILDREN ACT

SPEECH OF

HON. BENJAMIN A. GILMAN

OF NEW YORK

IN THE HOUSE OF REPRESENTATIVES

Tuesday, November 13, 2001

Mr. GILMAN. Mr. Speaker, I rise today in strong support of H.R. 2887, the Best Pharmaceuticals for Children Act. I urge my colleagues to join in supporting this important measure.

This legislation reauthorizes the pediatric exclusivity provision provided for in the Food and Drug Administration Modernization Act of 1997, which expires at the end of this calendar year. This legislation reauthorizes the provision through fiscal year 2007.

The bill directs the Secretary of HHS to create an annual list of approved drugs for which: (1) There is an approved or pending new drug application and (2) additional pediatric safety and effectiveness studies are needed. It further instructs the Secretary to award contracts to entities that have the appropriate experience for conducting clinical trials of such drugs.

The legislation also amends the Federal Food, Drug, and Cosmetic Act to: (1) Eliminate the user fee waiver for pediatric supplements to a human drug application; (2) provide priority status for pediatric supplements; (3) include neonates within the definition of pediatric studies; (4) provide for dissemination of pediatric supplement information; and (5) set forth requirements for the additional six-month exclusivity period for new or already-marketed pediatric drugs. Additionally, it amends title IV of the Public Health Service Act to direct the Secretary to establish the Foundation for Pediatric Research to support research on drugs lacking exclusivity for which pediatric studies are needed.

Finally, the bill directs the Secretary to: (1) Establish an Office of Pediatric Therapeutics within the Office of the Commissioner of Food and Drugs, which shall coordinate all FDA pediatric activities; and (2) contract with the Institute of Medicine to review federal regulations, reports, and support for research involving children, with particular attention to issues of compensation, informed consent, and risk/benefits assessments in terms of research versus therapeutic treatment.

Mr. Speaker, the pediatric exclusivity provision that was established in the FDA Modernization Act of 1997 has been overwhelmingly successful in generating clinical studies for the pediatric population in its 5 years of existence. According to the FDA, in the 6 years prior to the enactment of this provision, there were a total of six studies on the pediatric population at the request of the FDA, the 4 years since enactment have seen 197 requests to conduct more than 400 studies.

These studies are an invaluable tool in determining the safety and efficacy of newly approved drugs on the pediatric population. With the large number of drugs being approved each year, it is imperative that we have a working knowledge of the effects these medicines will have on our children's health and well-being. This bill will advance this purpose, and for that I urge my colleagues to support its adoption.